My Personal Plan to Turn Market Chaos Into 300%+ Growth

The article promotes a dividend-growth 'DCA+' strategy centered on buying stocks when their share prices lag rising payouts, with Visa and Amgen highlighted as examples. Visa has raised its dividend 378% over the last decade and repurchased 19% of shares; Amgen has bought back 5% of its float over five years while benefiting from AI-accelerated drug research. The piece is broadly constructive on both names and on capital-return strategies, but it is primarily opinion/strategy commentary rather than a new fundamental catalyst.

Analysis

The real signal here is not “timing” equities through dividends; it is using capital returns as a screening factor for balance-sheet discipline. Companies that can sustain accelerating payouts plus buybacks are effectively telegraphing durable free cash flow, and that typically compresses outcome dispersion relative to the market. In a regime where passive flows and index concentration dominate, that makes these names less about income and more about self-funded multiple support.

Visa is the cleaner expression of that trade because its return of capital is paired with a structurally advantaged toll-collector model. The second-order effect is that any selloff driven by macro noise, regulation headlines, or fintech sentiment should be shallower than the market expects, because repurchases tighten float while payout growth creates a recurring bid from income capital. The main risk is valuation: if rates back up or payments multiples de-rate, the dividend cushion will not prevent a compression episode over the next 1-3 months.

Amgen is more nuanced and arguably better as a relative-value long than an outright momentum bet. The market is likely underestimating how AI-driven R&D productivity can extend the duration of premium pricing across the biotech sector, which is a multi-year earnings lever rather than a near-term catalyst. The offset is patent/execution risk and pipeline binary exposure; any disappointment in late-stage readouts or a broader biotech de-risking wave can overwhelm buybacks for quarters at a time.

Consensus is probably underpricing the distinction between "dividend yield" and "dividend growth." Yield alone attracts slow capital; accelerating dividend growth attracts both income buyers and quality-growth buyers, creating a reflexive support loop. The better trade is to own these names into weakness, not strength, because the market usually waits for the payout signal to confirm durability before rerating, which creates a lag window that can last several months.

Key Decisions for Investors

• Long V on 3-6 month weakness; add on 3-5% drawdowns. Risk/reward favors accumulation because buybacks plus accelerating payout should cap downside unless multiples compress sharply.
• Use AMGN as a relative-value long versus a basket of higher-beta biotech names over 6-12 months. The thesis is cash-return support and AI-enabled productivity, but keep size moderate due to pipeline/event risk.
• Sell put spreads in V or AMGN 1-2 months out on elevated volatility. This monetizes the market's tendency to overreact to headline noise while aligning with the expected downside floor from capital returns.
• Pair long V / short a basket of payment processors with weaker cash-return discipline over 3-6 months. The goal is to isolate balance-sheet quality and reduce beta to the broader fintech tape.
• Avoid chasing either name after strong outperformance; the better entry is a pullback when price lags the dividend path. If the stock is already ahead of the payout, expected forward returns compress materially.